NO20004896D0 - Pyridazinonhydrokloridforbindelse og fremgangsmÕte for fremstilling derav - Google Patents

Pyridazinonhydrokloridforbindelse og fremgangsmÕte for fremstilling derav

Info

Publication number
NO20004896D0
NO20004896D0 NO20004896A NO20004896A NO20004896D0 NO 20004896 D0 NO20004896 D0 NO 20004896D0 NO 20004896 A NO20004896 A NO 20004896A NO 20004896 A NO20004896 A NO 20004896A NO 20004896 D0 NO20004896 D0 NO 20004896D0
Authority
NO
Norway
Prior art keywords
preparation
hydrochloride compound
pyridazinone hydrochloride
pyridazinone
compound
Prior art date
Application number
NO20004896A
Other languages
English (en)
Other versions
NO20004896L (no
Inventor
Takashi Horiuchi
Sachiko Matsumoto
Hiroo Matsumoto
Minako Kamikawaji
Original Assignee
Nissan Chemical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissan Chemical Ind Ltd filed Critical Nissan Chemical Ind Ltd
Publication of NO20004896D0 publication Critical patent/NO20004896D0/no
Publication of NO20004896L publication Critical patent/NO20004896L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22Nitrogen and oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/12Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20004896A 1998-03-31 2000-09-29 Pyridazinonhydrokloridforbindelse og fremgangsmÕte for fremstilling derav NO20004896L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP8592098 1998-03-31
PCT/JP1999/001629 WO1999050248A1 (en) 1998-03-31 1999-03-30 Pyridazinone hydrochloride compound and method for producing the same

Publications (2)

Publication Number Publication Date
NO20004896D0 true NO20004896D0 (no) 2000-09-29
NO20004896L NO20004896L (no) 2000-10-12

Family

ID=13872231

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004896A NO20004896L (no) 1998-03-31 2000-09-29 Pyridazinonhydrokloridforbindelse og fremgangsmÕte for fremstilling derav

Country Status (14)

Country Link
US (1) US6310065B1 (no)
EP (1) EP1066265A1 (no)
JP (1) JP2002509919A (no)
KR (1) KR20010042078A (no)
CN (1) CN1293661A (no)
AU (1) AU742553B2 (no)
CA (1) CA2326506A1 (no)
IL (1) IL138521A0 (no)
NO (1) NO20004896L (no)
NZ (1) NZ506959A (no)
SK (1) SK14742000A3 (no)
TW (1) TW499425B (no)
WO (1) WO1999050248A1 (no)
ZA (1) ZA200004927B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
MX2008014024A (es) 2006-05-04 2008-11-14 Boehringer Ingelheim Int Formas poliformas.
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
MX2011002558A (es) 2008-09-10 2011-04-26 Boehringer Ingelheim Int Terapia de combinacion para el tratamiento de diabetes y estados relacionados.
US8978895B2 (en) * 2008-10-01 2015-03-17 Rickey E. Wark Self-cleaning coal separator grids with multiple cleaning combs
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2382216A1 (en) 2008-12-23 2011-11-02 Boehringer Ingelheim International GmbH Salt forms of organic compound
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
EP3646859A1 (en) 2009-11-27 2020-05-06 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
AU2011249722B2 (en) 2010-05-05 2015-09-17 Boehringer Ingelheim International Gmbh Combination therapy
CN106975074A (zh) 2010-06-24 2017-07-25 勃林格殷格翰国际有限公司 糖尿病治疗
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
PH12014500137A1 (en) 2011-07-15 2017-08-18 Boehringer Ingelheim Int Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL110040A (en) * 1993-06-29 2000-07-16 Nissan Chemical Ind Ltd Pyridazinone derivatives their preparation and pharmaceutical compositions comprising them
JP3080131B2 (ja) * 1993-06-29 2000-08-21 日産化学工業株式会社 ピリダジノン誘導体

Also Published As

Publication number Publication date
CA2326506A1 (en) 1999-10-07
JP2002509919A (ja) 2002-04-02
US6310065B1 (en) 2001-10-30
TW499425B (en) 2002-08-21
EP1066265A1 (en) 2001-01-10
WO1999050248A1 (en) 1999-10-07
CN1293661A (zh) 2001-05-02
NZ506959A (en) 2002-02-01
SK14742000A3 (sk) 2001-03-12
NO20004896L (no) 2000-10-12
AU2960699A (en) 1999-10-18
ZA200004927B (en) 2001-12-24
IL138521A0 (en) 2001-10-31
AU742553B2 (en) 2002-01-03
KR20010042078A (ko) 2001-05-25

Similar Documents

Publication Publication Date Title
NO20004896D0 (no) Pyridazinonhydrokloridforbindelse og fremgangsmÕte for fremstilling derav
NO20010446D0 (no) Substituert anilidforbindelser og metoder
NO20032753D0 (no) Forbindelse og anvendelse derav
NO20012158D0 (no) Substituerte 2-fenylbenzimidazoler, fremgangsmåte til fremstilling og anvendelse derav
DK1137635T3 (da) N-substituerede 2-cyanopyrrolidiner
DK1454907T3 (da) Quninazolin og pyridopyrmidin-derivativer
NO20000627D0 (no) ForhÕndsbelagte kontrollert - frigjørings - gjødningsmidler og fremgangsmÕter for deres fremstilling
DK0985697T3 (da) Oxiranderivater og fremgangsmåde til fremstilling deraf
NO20003067D0 (no) Antipicornavirus-forbindelser og fremgangsmÕter for deres anvendelse og fremstilling
NO20021736D0 (no) Nytt preparat og fremgangsmåte for stabilisering av det
DK1073672T3 (da) Antipicornavirale forbindelser, deres fremstilling og anvendelse
NO20003070L (no) Substituert tiazolidinderivat, fremgangsmÕte for fremstilling og anvendelse derav
EE04234B1 (et) L-fenüülefriinvesinikkloriidi valmistamise meetod
NO20012963D0 (no) Fremgangsmåte for fremstilling av 3-alkanoylindoler og 3- alkylindoler
IS5942A (is) 3,3-bíarýlpíperidín og 2,2-bíarýlmorfólín afleiður
DK1003383T4 (da) Smagsforstærkende N-ethyl-p-menthan-3-carboxamidindeholdende forbindelser og fremgangsmåde til fremstilling og anvendelse deraf
NO991278L (no) FremgangsmÕte og system for sikker netthandel
NO985248L (no) Indolylpyrrolydenmetylpyrrolderivater og fremgangsmÕte for deres fremstilli
NO995851L (no) Fremstillingsfremgangsmåte for isoksasolidinedion forbindelse
NO20013085D0 (no) Fosfororganiske forbindelser og deres anvendelse
GB0030218D0 (en) Photographic element compound and process
NO20012099D0 (no) Fremgangsmåte for fremstilling av 4-arylpiperidin-3- carbinoler og beslektede forbindelser
NO20006479D0 (no) Tienopyridinforbindelser, deres fremstilling og anvendelse
FI980856A0 (fi) Andningsskydd utrustad med en identifierare
DK1200446T3 (da) Oxathiepino[6,5-b]dihydropyridiner og beslægtede forbindelser og fremgangsmåder

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application